Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Paratek Pharmaceuticals, Inc. - Common Stock (NQ:PRTK)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Paratek Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Earnings Outlook For Paratek Pharmaceuticals ↗
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Paratek Pharmaceuticals: Q4 Earnings Insights ↗
Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here's what investors need to know about the announcement... 
Via Benzinga
News headline image
Earnings Scheduled For March 14, 2022 ↗
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
News headline image
Paratek Pharmaceuticals's Earnings: A Preview ↗
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
News headline image
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board ↗
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
News headline image
Zai Lab's Nuzyra Approved In China For Bacterial Infections ↗
The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral... 
Via Benzinga
News headline image
Recap: Paratek Pharmaceuticals Q3 Earnings ↗
Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Paratek Pharmaceuticals's Return On Capital Employed Insights ↗
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Dermata Therapeutics (NASDAQ:DRMA 
Via Benzinga
News headline image
Earnings Scheduled For November 8, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
News headline image
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax ↗
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK... 
Via Benzinga
News headline image
48 Biggest Movers From Friday ↗
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday. Clearwater Analytics Holdings, Inc. (NYSE: CWAN) surged 40.9% to settle at $25.37... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume for Molecular Templates's stock is 937.9K as... 
Via Benzinga
News headline image
34 Stocks Moving In Friday's Mid-Day Session ↗
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08. Unique Fabricating, Inc. (NASDAQ: UFAB) jumped 37.7% to $3.47. Form 4 filings from late Thursday... 
Via Benzinga
News headline image
How Good Are Paratek Pharmaceuticals's Earnings? | Return On Capital Employed ↗
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection ↗
The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Protagenic Therapeutics (NASDAQ:PTIX... 
Via Benzinga
News headline image
Paratek Pharmaceuticals (PRTK) Q2 2021 Earnings Call Transcript ↗
PRTK earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Paratek Pharmaceuticals: Q2 Earnings Insights ↗
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 137.74%... 
Via Benzinga
News headline image
Earnings Scheduled For August 9, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.